Biomedical subjects

A M Saĭitkulov

Publications and source records attributed to A M Saĭitkulov.

13 recordsLinked to original sources

PubMed1992

[Interferon-inducing activity of hydroxybenzylamine derivative].

Interferon-inducing activity of the interferon inductor savrats, an oxybenzylamine derivative of was studied. It was shown on experimental animals that along with its low toxicity, savrats had a high interferon inducing capacity. There were early and late peaks of interferon production (4-8 and 48-96 hours later, respectively) depending on the route of the inductor administration. It was noted that for optimization of the schemes for using interferon inductors, careful choosing of the drug pairs participating in the induction and employment of various routes for administration of the same drug are required.

Administration, Oral↗

PubMed1992

[Pharmacokinetics of the interferon inducer PHL-6 and interferon synthesis in target organs under various methods of drug administration].

The pharmacokinetics of PHL-6 and interferon synthesis dynamic in the target organs (tissues) of mice were studied during its and intraperitoneal administration. In the experimental setting, there was a direct correlation between the interferon production in the murine organs with single PHL-6 and distribution of 14C PHL-6. The highest radioactivity with its oral administration was detected in the liver and intestine. Interferon was actively synthesized in the intestine, liver and serum, showing the levels of 20000, 1024-2048 and 512-1024 IU/ml, respectively. The prolonged action of the drug was in good agreement with the low PHL-6 excretion from the body. It was also shown that almost the whole radiation dose 1 (greater than 98%) was excreted with feces and urine after single and chronic administrations of uniformly labeled PHL-6 which proved important clinical drug use.

Administration, Oral↗

PubMed1991

[Relation between interferon-inducing activity of natural interferon inducers and their chemical structure].

The interferon-inducing activity of new derivatives of gossypol, a low molecular weight natural polyphenol, and its model compounds was studied in regard to their chemical structure. The active groups required for development of optimal interferon inductors on the basis of the natural polyphenols were defined. As a result of the studies the new interferon inductor AC-1 which is a condensation product of gossypol, a natural polyphenol, and a cellulose derivative was isolated. The interferon-inducing activity of AC-1 was investigated with respect to its dose and the administration route. High interferon-inducing activity of the interferon inductor after its administration by any route in doses of 10 to 100 mg/kg was demonstrated. The serum interferon titers reached 2560 units/ml.

Administration, Oral↗

PubMed1990

[Inhibition of Chlamydia trachomatis multiplication by interferon inducer larifan in mice with experimental infection].

Interferon (IF)-inducing capacity of C. trachomatis was shown in experiments on mice CBA. The levels of IF production in the parenchymatous organs correlated with accumulation of the pathogen in them. The use of larifan, a natural double-stranded IF inductor, according to the treatment scheme provided high levels of endogenic IF in infected mice. It inhibited multiplication of Chlamydiae in the lungs and lymph nodes detected cytoscopically by light and fluorescence microscopy and with infection titration. The effect of the inductor combined with tetracycline was of additive nature. Double intraperitoneal administration of larifan with an account of the hyporeactivity phase and daily administration of tetracycline proved to be the most efficient. It is possible to successfully use IF inductors in accordance with the treatment schemes in infection caused by C. trachomatis which makes promising their clinical application in therapy of chlamydiosis.

Animals↗

PubMedDate not supplied

[Treatment of disorders in interferon status of patients with urogenital chlamydial infection].

The interferon status was studied in 54 patients with urogenital chlamydiosis, presenting with disturbances in the reproductive system. The blood serum content of gamma-interferon was 32-fold in the above patient population vs control subjects on conventional therapy. Supplementing such a therapy with cycloferon, an inducer of endogenous interferon, and with immunomodulin have been shown to activate production of interferon.

Adjuvants, Immunologic↗

PubMedDate not supplied

[A new interferon inducer active via peroral administration].

Biological activities of a new oral interferon inducer, Tash-4, were studied. In maximal soluble doses (2000 mg/kg body weight) the inducer was shown to have no toxicity. An important advantage of Tash-4 over other known interferon inducers consists in its capacity to induce interferon in high concentrations in the intestinal tract. Upon repeated administration of Tash-4 hyporeactivity is detectable within 3 days and persists for up to 6 days. A change of inducers may be used to overcome the hyporeactivity. Sequential administration of Tash-4 and Tash-3 induced in animals interferon production in response first to one inducer, then to the other. It is assumed that the mechanisms of induction and suppression of interferon induced by these preparations differ.

Administration, Oral↗

PubMedDate not supplied

[Effect of low-molecular interferon inducers in experimental hepatitis in mice].

Among low molecular interferon inducers preparations were selected which were capable of inducing interferon (IFN) synthesis after oral administration and advantageous for further clinical use. The dynamics of interferon production was studied after oral administration of three national low molecular interferon inducers. The selected preparations: a synthetic inducer, amiksin, and 2 natural compounds (gossypol derivatives), kagocel-1 and PXL-6, stimulated high levels of interferon production (from 10,000 to 20,000 IU/ml) in the intestinal tract of the animals 4 hours after induction and protected the animals from hepatitis virus of mice (the Meshcherin strain) after oral administration 24 hours before infection (35-55%). Amiksin and PXL-6 produced significant protection (p less than 0.01 or 0.001)--40 or 50%, respectively, when administered 4 hours before virus infection.

Animals↗

PubMedDate not supplied